Skip to main content
SpringerLink
Log in

Breast Cancer and Leukemia: The forest for the trees?

  • Editorial
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Early Breast Cancer Trialists' Collaborative Group, Polychemotherapy for early breast cancer: an overview of the randomised trials.Lancet 1998;352:930–42.

    Article  Google Scholar 

  2. Weldon, C, Jaffe B, Kahn M. Therapy-induced leukemias and myelodysplastic syndromes following breast cancer treatment: an underemphasized clinical problem.Ann Surg. Oncol 2002;9:738–44.

    Article  PubMed  Google Scholar 

  3. Curtis RE, Boice JD Jr, Stovall M, Moloney WC, Hoover RN. Risk of leukemia after chemotherapy and radiation treatment for breast cancer.N Engl J Med 1992;326:1745–51.

    Article  PubMed  CAS  Google Scholar 

  4. Wils JA, Bliss JM, Marty M, et al. Epirubicin plus tamoxifen versus tamoxifen alone in node-positive postmenopausal patients with breast cancer: a randomized trial of the International Collaborative Cancer Group.J Clin Oncol 1999;17:1988–98.

    PubMed  CAS  Google Scholar 

  5. Piccart MJ, Di Leo A, Beauduin M, et al. Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer.J Clin Oncol 2001;19:3103–10.

    PubMed  CAS  Google Scholar 

  6. Fisher B, Rockette H, Fisher E, Wickerham D, Redmond C, Brown A. Leukemia in breast cancer patients following adjuvant chemotherapy or postoperative radiation: the NSABP experience.J Clin Oncol 1985;3:1640–58.

    PubMed  CAS  Google Scholar 

  7. Levine M, Bramwell V, Pritchard K, et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer.J Clin Oncol 1998;16:2651–8.

    PubMed  CAS  Google Scholar 

  8. Ragaz J, Coldman A. Survival impact of adjuvant tamoxifen on competing causes of mortality in breast cancer survivors, with analysis of mortality from contralateral breast cancer, cardiovascular events, endometrial cancer, and thromboembolic episodes.J Clin Oncol 1998;16:2018–24.

    PubMed  CAS  Google Scholar 

  9. Magriples U, Naftolin F, Schwartz P, Carcangiu M. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients.J Clin Oncol 1993;11:485–90.

    PubMed  CAS  Google Scholar 

  10. Chlebowski RT, Collyar DE, Somerfield MR, Pfister DG. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene.J Clin Oncol 1999;17:1939–55.

    PubMed  CAS  Google Scholar 

  11. Wickerham DL, Fisher B, Wolmark N, et al. Association of tamoxifen and uterine sarcoma.J Clin Oncol 2002;20:2758–60.

    PubMed  Google Scholar 

  12. Baum M, Group AT. The ATAC (arimidex, tamoxifen, alone or in combination) adjuvant breast cancer trial in post-menopausal (PM) women (abstract). Breast Cancer Treatment Reports 2001:8a.

  13. Cobleigh M, Vogel C, Tripathy D, et al. Efficacy and safety of Herceptin TM (humanized anti-HER2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer (abstract).Proceedings of ASCO 1998;17:367a

    Google Scholar 

  14. Baselga J, Norton L, Albanell J, Young-Mee K, Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin TM) enhanses the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.Cancer Res 1998;58:2825–31.

    PubMed  CAS  Google Scholar 

  15. Slamon DJ, Leyland-Jones B, Shak, S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.N Engl J Med 2001;344:783–92.

    Article  PubMed  CAS  Google Scholar 

  16. Baselga J. Pargeting the epidermal growth factor receptor with tyrosine kinase inhibitors: small molecules, big hopes.J Clin Oncol 2002;20:2217–9.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., Box 206, 10021, New York, NY

    Clifford Hudis MD

Authors
  1. Clifford Hudis MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Clifford Hudis MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hudis, C. Breast Cancer and Leukemia: The forest for the trees?. Annals of Surgical Oncology 9, 717–718 (2002). https://doi.org/10.1007/BF02574491

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02574491

Search

Navigation